Over
time, developments in nano-biomedical research have led to
the creation of a number of systems to cure serious illnesses. Tandem
use of nano-theragnostics such as diagnostic and therapeutic approaches
tailored to the individual disease treatment is crucial for further
development in the field of biomedical advancements. Graphene has
garnered attention in the recent times as a potential nanomaterial
for tissue engineering and regenerative medicines owing to its biocompatibility
among the several other unique properties it possesses. The zero-dimensional
graphene quantum dots (GQDs) and their nitrogen-doped variant, nitrogen-doped
GQDs (N-GQDs), have good biocompatibility, and optical and physicochemical
properties. GQDs have been extensively researched owing to several
factors such as their size, surface charge, and interactions with
other molecules found in biological media. This work briefly elucidates
the potential of electroactive GQDs as well as N-GQDs as neurotrophic
agents. In vitro investigations employing the N2A cell line were used
to evaluate the effectiveness of GQDs and N-GQDs as neurotrophic agents,
wherein basic investigations such as SRB assay and neurite outgrowth
assay were performed. The results inferred from immunohistochemistry
followed by confocal imaging studies as well as quantitative real-time
PCR (qPCR) studies corroborated those obtained from neurite outgrowth
assay. We have also conducted a preliminary investigation of the pattern
of gene expression for neurotrophic and gliotrophic growth factors
using ex vivo neuronal and mixed glial cultures taken from the brains
of postnatal day 2 mice pups. Overall, the studies indicated that
GQDs and N-GQDs hold prospect as a framework for further development
of neuroactive compounds for relevant central nervous system (CNS)
purposes.